Adjusted mean difference versus placebo in change from baseline in HbA1c at week 12 was -0.62 % ( 95 % CI -0.72 , -0.52 ) ( -6.8 mmol/mol [ 95 % CI -7.9 , -5.7 ] ) with 10 mg empagliflozin and -0.65 % ( 95 % CI -0.75 , -0.55 ) ( -7.1 mmol/mol [ 95 % CI -8.2 , -6.0 ] ) with 25 mg empagliflozin ( both P < 0.001 ) .